Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TNF Blocker Fungal Infection: FDA Uses REMS For Relabeling, Education

Executive Summary

FDA is using its new drug safety authority to require label changes within 30 days for all four products in the tumor necrosis factor inhibitor class
Advertisement

Related Content

Remicade Pediatric Indication Likely Faces Safety Scrutiny At Advisory Committee
Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
Centocor's Simponi Becomes First TNF Blocker To Escape REMS Duties
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
Simponi, Cimzia REMS A Portent For Rest Of TNF Class
Pfizer’s Drug Safety Web Site Aims To Reclaim Risk Communication Authority
Enbrel REMS delays pediatric approval
TNF Blockers’ Link To Cancer In Children Is Under FDA Investigation
Enbrel Label Gets “Black Box” On Tuberculosis Risk
Remicade Relabeling Is Increasing Rate Of TB Screening, J&J Says
Advertisement
UsernamePublicRestriction

Register

PS050081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel